Trial Profile
A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Regorafenib (Primary) ; Trametinib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CheckMate9N9
- Sponsors Bristol-Myers Squibb
- 26 Sep 2023 Planned End Date changed from 30 Jan 2026 to 11 Mar 2024.
- 26 Sep 2023 Planned primary completion date changed from 31 Oct 2023 to 11 Mar 2024.
- 07 Mar 2023 Status changed from recruiting to active, no longer recruiting.